Filing Flows › Insight Molecular Diagnostics (IMDX) › Q1 2026 › vs Q1 2025
Insight Molecular Diagnostics (IMDX) Q1 2026 vs Q1 2025 (year over year)
Insight Molecular Diagnostics's revenue fell $2.1M (-99%) from $2.1M in Q1 2025 to $32K in Q1 2026.
Insight Molecular Diagnostics, Q1 2026: revenue $32K (-98% year over year), net loss $4.3M, operating cash flow −$7.6M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $32K | $2.1M | −$2.1M | -99% |
| Other income, net | $123K | $128K | −$5K | -4% |
| Net loss | $4.3M | $6.7M | −$2.4M | -36% |
| Costs & expenses | $4.4M | $8.9M | −$4.5M | -50% |
| Operating costs | $4.4M | $8.9M | −$4.5M | -50% |
| Cost of revenue | $17K | $813K | −$796K | -98% |
| Operating expenses | $4.4M | $8.1M | −$3.7M | -45% |
| Operating cash sources | $8.9M | $6.8M | $2.1M | +31% |
| Depreciation & amortization | $631K | $491K | $140K | +29% |
| Share-based compensation | $615K | $473K | $142K | +30% |
| Cash used in operations | $7.6M | $5.8M | $1.8M | +31% |
| Net loss absorbed | $4.3M | $6.7M | −$2.4M | -36% |
| Working capital & other | $4.6M | $132K | $4.5M | 35× |
Questions
How much did Insight Molecular Diagnostics's revenue grow year over year in Q1 2026?
Insight Molecular Diagnostics's revenue fell $2.1M (-99%) from $2.1M in Q1 2025 to $32K in Q1 2026.